வார்ப்பு உணர்திறன் ப்ராஸ்டேட் புற்றுநோய் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from வார்ப்பு உணர்திறன் ப்ராஸ்டேட் புற்றுநோய். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In வார்ப்பு உணர்திறன் ப்ராஸ்டேட் புற்றுநோய் Today - Breaking & Trending Today

New Standard for Metastatic Castration-Sensitive Prostate Cancer?

email article
Hormonal therapies combined with chemotherapy significantly improved radiographic progression-free survival (rPFS) for men with de novo metastatic castration-sensitive prostate cancer (mCSPC), results from a phase III study showed.
In the PEACE-1 trial, the triplet therapy of abiraterone (Zytiga) plus androgen-deprivation therapy (ADT) and docetaxel extended rPFS by a median 2.5 years for these patients, and could be practice changing, reported Karim Fizazi, MD, PhD, of Institut Gustave Roussy in Villejuif, France.
Regardless of overall survival [OS] results, this data question whether we should deny patients approximately 2 and a half years without radiographic progression or death, or whether combining ADT/docetaxel and abiraterone/prednisone should simply become the new standard of care, Fizazi said during a presentation at the virtual American Society of Clinical Oncology annual meeting. ....

France General , United States , New South Wales , Karim Fizazi , Mike Bassett , Institut Gustave Roussy , Lisa Horvath , Sydney Cancer Center , American Society Of Clinical Oncology , American Society , Clinical Oncology , Castration Sensitive Prostate Cancer , Prostate Cancer , பிரான்ஸ் ஜநரல் , ஒன்றுபட்டது மாநிலங்களில் , புதியது தெற்கு வேல்ஸ் , மைக் பாசெட் , லிசா ஹார்வத் , அமெரிக்கன் சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல் , அமெரிக்கன் சமூகம் , மருத்துவ புற்றுநோயியல் , வார்ப்பு உணர்திறன் ப்ராஸ்டேட் புற்றுநோய் , ப்ராஸ்டேட் புற்றுநோய் ,

Janssen presentará pruebas sólidas de su cartera de tumores sólidos y su cartera de productos en ASCO GU 2021 - Iberonews

ó
stata avanzado; presentaciones orales para destacar los resultados de los estudios de fase 3 ACIS, TITAN y SPARTAN
SOLO PARA MEDIOS DE COMUNICACIÓN MÉDICOS Y COMERCIALES FARMACÉUTICOS DE LA REGIÓN DE EMEA
NO SE PERMITE LA DISTRIBUCIÓN EN EL BENELUX NI EN EL REINO UNIDO
Janssen Pharmaceutical Companies de Johnson & Johnson ha anunciado hoy que destacará la solidez de su cartera de tumores sólidos en el Simposio sobre Cánceres Genitourinarios de la Sociedad Americana de Oncología Clínica (American Society of Clinical Oncology Genitourinary, ASCO GU) con 12 presentaciones de datos, entre las que se incluyen tres presentaciones orales del programa de desarrollo clínico de apalutamida patrocinadas por la compañía. ....

Prognostic Association Between Common Laboratory , Single Payer Health , Determinants Associated , Long Term Response , Non Metastatic Castration Resistant Prostate , Placebo Controlled Double Blind Phase , Abiraterone Acetate Plus Prednisone , Prostate Cancer , Advanced Disease , Related Quality , Life Analysis , Randomized Phase , Androgen Signaling Inhibitors , Androgen Deprivation Therapy , Castration Sensitive Prostate Cancer , Unsatisfactory Response , Androgen Receptor Inhibition , Allocation Modular Sequential , Radiation Therapy Followed , Prostate Cancer After Radical , Locally Advanced , Metastatic Urothelial , Urothelial Carcinoma , Deleterious Germline , Progress Poster Session , Advanced Prostate Cancer ,

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
Multiple data presentations to show long-term benefit and consistency of ERLEADA® (apalutamide) in advanced prostate cancer; oral presentations to highlight Phase 3 ACIS, TITAN and SPARTAN study results
News provided by
Share this article
Share this article
RARITAN, N.J., Feb. 2, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA
® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. ....

United States , Craig Tendler , Jennifer Mcintyre , Christopher Delorefice , Obrian Kenney , Global Medical Affairs , Breadth Of Ongoing Clinical Development Program , Janssen Biotech Inc , Tesaro Inc , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Laboratory Abnormalities , Prognostic Association Between Common Laboratory , Clinical Development , None Of The Janssen Pharmaceutical Companies , Astex Pharmaceuticals , Janssen Research Development Llcor , Exchange Commission , Companies Of Johnson , Single Payer Health , American Society , Clinical Oncology Genitourinary , Cancers Symposium , Vice President , Janssen Research ,